Corbion Valuation

Is CRBN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRBN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRBN (€24.52) is trading below our estimate of fair value (€36.66)

Significantly Below Fair Value: CRBN is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRBN?

Other financial metrics that can be useful for relative valuation.

CRBN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.3x
Enterprise Value/EBITDA10x
PEG Ratio1x

Price to Earnings Ratio vs Peers

How does CRBN's PE Ratio compare to its peers?

The above table shows the PE ratio for CRBN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18x
AKZA Akzo Nobel
18.3x9.6%€10.8b
APAM Aperam
30x46.5%€2.0b
HYDRA Hydratec Industries
10.3xn/a€207.7m
4206 Aica Kogyo Company
13.5x7.5%JP¥212.3b
CRBN Corbion
17.8x18.5%€1.4b

Price-To-Earnings vs Peers: CRBN is good value based on its Price-To-Earnings Ratio (17.8x) compared to the peer average (18x).


Price to Earnings Ratio vs Industry

How does CRBN's PE Ratio compare vs other companies in the European Chemicals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a22.9%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a22.9%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: CRBN is good value based on its Price-To-Earnings Ratio (17.8x) compared to the European Chemicals industry average (18.4x).


Price to Earnings Ratio vs Fair Ratio

What is CRBN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRBN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.8x
Fair PE Ratio17.8x

Price-To-Earnings vs Fair Ratio: CRBN is expensive based on its Price-To-Earnings Ratio (17.8x) compared to the estimated Fair Price-To-Earnings Ratio (17.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRBN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€24.52
€24.92
+1.6%
20.2%€30.00€15.00n/a6
Sep ’25€22.86
€24.65
+7.8%
22.6%€30.00€13.40n/a6
Aug ’25€20.52
€23.65
+15.3%
22.0%€29.00€13.40n/a6
Jul ’25€19.21
€23.65
+23.1%
22.0%€29.00€13.40n/a6
Jun ’25€20.38
€23.65
+16.0%
22.0%€29.00€13.40n/a6
May ’25€20.54
€23.65
+15.1%
22.0%€29.00€13.40n/a6
Apr ’25€19.85
€23.48
+18.3%
22.5%€29.00€13.40n/a6
Mar ’25€19.56
€22.75
+16.3%
24.5%€29.00€13.40n/a6
Feb ’25€17.20
€22.75
+32.3%
24.5%€29.00€13.40n/a6
Jan ’25€19.38
€24.42
+26.0%
14.9%€29.00€18.50n/a6
Dec ’24€16.62
€24.42
+46.9%
14.9%€29.00€18.50n/a6
Nov ’24€16.14
€24.42
+51.3%
14.9%€29.00€18.50n/a6
Oct ’24€18.86
€29.58
+56.9%
16.4%€37.00€23.00€25.506
Sep ’24€21.84
€29.58
+35.5%
16.4%€37.00€23.00€22.866
Aug ’24€21.50
€29.13
+35.5%
16.1%€36.00€23.00€20.524
Jul ’24€21.86
€29.13
+33.2%
16.1%€36.00€23.00€19.214
Jun ’24€25.42
€35.40
+39.3%
9.1%€38.11€30.00€20.384
May ’24€28.50
€35.40
+24.2%
9.1%€38.11€30.00€20.544
Apr ’24€30.24
€36.65
+21.2%
10.7%€40.00€30.00€19.854
Mar ’24€35.68
€38.28
+7.3%
10.5%€43.00€32.00€19.564
Feb ’24€35.44
€38.28
+8.0%
10.5%€43.00€32.00€17.204
Jan ’24€31.84
€33.03
+3.7%
12.4%€38.11€27.00€19.384
Dec ’23€33.10
€33.03
-0.2%
12.4%€38.11€27.00€16.624
Nov ’23€26.74
€36.22
+35.5%
20.3%€49.00€27.00€16.145
Oct ’23€25.66
€38.22
+49.0%
15.1%€49.00€32.00€18.865

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies